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McLelland et al., http ://www .jcb .org /cgi /content /full /jcb .201603105 /DC1 Figure S1 . Silencing of Stx17 does not perturb other MDV pathways. (A) Representative confocal images of cells expressing LAMP1-mRFP (magenta) treated with glucose oxidase (GO), then fixed and immunostained for PDH E2/E3bp (yellow) and TOM20 (cyan; Hoescht, blue). TOM20 + /PDH E2/ E3bp − structures that are positive (white arrowheads) or negative (empty arrowheads) for LAMP1 are indicated. Bars: (main) 10 µm; (inset) 2 µm. (B) Quantification of the percent of TOM20 + /PDH E2/E3bp − structures that colocalize with LAMP1-mRFP in Stx17-silenced COS7 cells treated with 50 mU/ml glucose oxidase or left untreated. Bars represent mean; n = 32-39 cells per condition; n.s., not significant. (C) COS7 cells transfected with MAPL-YFP (yellow) and the indicated siRNA were fixed and immunostained for TOM20 (cyan) and PMP70 (magenta, a peroxisomal marker; Hoescht, blue). Red arrowheads indicate PMP70-labeled peroxisomes that also contain MAPL-YFP. Bars: (main) 10 µm; (inset) 2 µm. (D) Quantification of the percentage of PMP70-labeled peroxisomes that also contain MAPL-YFP per cell in control siRNA (red) and siStx17 (blue) cells from C. Bars represent the mean; n = 30 and 28 cells for ctrl siRNA and siStx17, respectively; **, P < 0.01. 
